Related Experiment Video
Updated: Mar 25, 2026
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Risk of Incident Cancer in Inflammatory Bowel Disease Patients Starting Anti-TNF Therapy While Having Recent
Florian Poullenot1, Philippe Seksik, Laurent Beaugerie
11CHU de Bordeaux, Hôpital Haut-Le[Combining Acute Accent]vêque, Service d'He[Combining Acute Accent]pato-gastroente[Combining Acute Accent]rologie, University of Bordeaux, Bordeaux, Pessac, France; 2Department of Gastroenterology, AP-HP, Hôpital Saint-Antoine, ERL 1157 INSERM/UMRS 7203, DHU 12B, UPMC, Paris, France; 3Department of Gastroenterology, Henri Mondor Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Creteil University, Paris, France; 4CHRU de Lille, Hôpital Claude Huriez, Service des Maladies de l'Appareil Digestif-Endoscopie Digestive, Lille, France; 5Department of Gastroenterology, Cochin Hospital, Assistance Publique Hôpitaux de Paris and Paris V University, Paris, France; 6Hôpital Beaujon, Gastroente[Combining Acute Accent]rologie, Maladies Inflammatoires Chroniques de l'Intestin et Assistance Nutritive, AP-HP, Universite[Combining Acute Accent] Paris VII, Clichy, France; 7Department of Gastroenterology, CHU of Liège, University of Liège, Belgium; 8GIGA Research, University of Liege, Belgium; 9Service d'He[Combining Acute Accent]pato-Gastroente[Combining Acute Accent]rologie, CHU Amiens, Université de Picardie Jules Verne, Amiens, France; 10Department of Gastroenterology, Bichat Hospital, Assistance Publique Hôpitaux de Paris, Paris, France; 11Department of Gastroenterology, Lyon Sud Hospital, Hospices Civils de Lyon, Pierre Benite, France; 12INSERM U1111, CIRI, Lyon, France; 13INSERM U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Université Henri Poincaré 1, Vandoeuvre-lès-Nancy, France; 14Inserm CIC 1114 and Institut des Maladies de l'Appareil Digestif, University Hospital, Nantes, France; 15CHU de Nice, Hôpital de l'Archet 2, Service de Gastroente[Combining Acute Accent]rologie et Nutrition Clinique, Nice, France; 16Department of Hepato-Gastroenterology and Digestive Oncology Hôpital Robert Debré, Reims, France; 17CHU de Rouen, Hôpital Charles Nicolle, Service de Gastroente[Combining Acute A
Background:
Patients with inflammatory bowel disease (IBD) and history of malignancy within the last 5 years are usually contraindicated for receiving anti-tumor necrosis factor (anti-TNF) agents. The aim of this study is to assess survival without incident cancer in a cohort of IBD patients exposed to anti-TNF while having previous malignancy within past 5 years.
Methods:
Data from IBD patients with previous malignancy diagnosed within the last 5 years before starting an anti-TNF agent were collected through a Groupe d'Etude Thérapeutiques des Affections Inflammatoires du tube Digestif multicenter survey. Inclusion date corresponded to the first anti-TNF administration after cancer diagnosis.
Results:
Twenty centers identified 79 cases of IBD patients with previous malignancy diagnosed 17 months (median; range: 1-65) before inclusion. The most frequent cancer locations were breast (n = 17) and skin (n = 15). After a median follow-up of 21 (range: 1-119) months, 15 (19%) patients developed incident cancer (8 recurrent and 7 new cancers), including 5 basal-cell carcinomas. Survival without incident cancer was 96%, 86%, and 66% at 1, 2, and 5 years, respectively. Crude incidence rate of cancer was 84.5 (95% CI, 83.1-85.8) per 1000 patient-years.
Conclusions:
In a population of refractory IBD patients with recent malignancy, anti-TNF could be used taking into account a mild risk of incident cancer. Pending prospective and larger studies, a case-by-case joint decision taken with the oncologist is recommended for managing these patients in daily practice.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...